Lesson
Diagnose Acne and Grade Its Consequences
Acne is diagnosed through lesion morphology and distribution. Severity includes inflammation, nodules, scars, pigment change, pain, prior failure, and psychosocial burden rather than one count alone.
- Comedones
- Papules and pustules
- Nodules
- Scarring
- Differential diagnosis
Separate acne from monomorphic or noncomedonal mimics
Papules, pustules, nodules, scars, and trunk disease matter
Include pain, pigment, distress, and social function
Protect diagnosis and prevent permanent injury
Start with morphology
Open and closed comedones support acne vulgaris. Papules and pustules add inflammation, while nodules signal deeper injury and greater scar risk. Examine the face, chest, back, shoulders, hairline, and areas exposed to friction or occlusion.
Measure consequences
Document active lesions together with scars, postinflammatory pigment change, tenderness, pain, mood, social avoidance, school or work effect, and prior adequate treatment. A modest lesion count can conceal major cumulative burden.
Protect the differential
Rosacea, periorificial dermatitis, bacterial or fungal folliculitis, hidradenitis, medication eruptions, and endocrine disorders can resemble acne. Monomorphic lesions, flushing, scale, systemic findings, rapid onset, unusual age, or absent comedones should prompt reassessment.
Order tests for a clinical reason
Typical acne does not routinely require bacterial culture, susceptibility testing or a hormone panel. New uniform pustules around facial openings after prolonged tetracycline treatment raise concern for Gram-negative folliculitis and may warrant culture. Hirsutism, menstrual irregularity, virilization or other endocrine clues justify targeted evaluation rather than assuming that every acne patient has excess circulating androgens.
Escalate before permanent harm
Deep nodules, new scars, extensive truncal disease, severe distress, pregnancy complexity, diagnostic uncertainty, or failure of a well-used regimen warrants clinician or dermatology evaluation rather than endless product switching.
Quick check
Checking for saved practice…
Lesson
Connect the Follicle to the Lesion
Follicular plugging, sebum, C. acnes, inflammation, and androgen signaling form a connected circuit. Visible lesions represent different stages and depths of that process.
- Microcomedone
- Sebum
- C. acnes
- Inflammation
- Scar formation
Abnormal keratinization begins before a visible lesion
Androgen signaling and lipid environment shape the follicle
Microbial and host responses amplify inflammation
Nodules increase scar and pigment risk
Begin before the visible lesion
Abnormal follicular keratinization creates a microcomedone before a blackhead or whitehead appears. Retinoids target this field process, which is why they are applied across acne-prone skin rather than only to individual spots.
Separate microbial presence from infection
C. acnes participates in the follicular ecosystem and inflammatory signaling. Acne is not a contagious hygiene failure, and harsh scrubbing does not eradicate its biology.
Trace depth to harm
Inflammation extending deeper into the follicle produces tender nodules and greater risk of permanent scar. Manipulation, delay, and inadequate control can magnify tissue injury and pigment change.
Build complementary mechanisms
Retinoids address follicular plugging, benzoyl peroxide reduces bacterial burden, antibiotics reduce bacterial and inflammatory activity, clascoterone targets androgen signaling, and hormonal or isotretinoin strategies address broader drivers.
Quick check
Checking for saved practice…
Lesson
Use Topical Retinoids as a Foundation
Topical retinoids normalize follicular keratinization and reduce inflammation. Product, molecule, vehicle, age, stability, irritation, and reproductive context determine safe use.
- Adapalene
- Tretinoin
- Tazarotene
- Trifarotene
- Irritation management
Treat the full acne-prone field, not one spot
Stability, receptor profile, age, site, and access differ
Use moisturizer and a tolerable frequency
Continue a nonantibiotic foundation after control
Choose the exact retinoid
Adapalene, tretinoin, tazarotene, and trifarotene differ in receptor selectivity, photostability, oxidation stability, concentrations, vehicles, labeled ages, body sites, and reproductive precautions. They are not interchangeable by strength alone.
Teach field application
Use the exact label; a pea-sized amount is common but is not a universal dose for every retinoid product. Apply a thin layer to acne-prone skin rather than placing large amounts on individual lesions, and keep the product away from eyes, lips, angles of the nose, and injured skin.
Engineer tolerability
Dryness, burning, peeling, and early apparent worsening can undermine adherence. Begin at a tolerable frequency, use a gentle cleanser and noncomedogenic moisturizer, reduce other irritants, and advance only as the skin adapts.
Apply Aklief by treatment area
Aklief is trifarotene 0.005% cream, labeled from age nine. Apply a thin layer each evening to clean, dry skin. One pump covers the face; two cover the upper trunk, with one additional pump for affected middle or lower back. Use moisturizer from the start. Avoid damaged skin, eczema, sunburn and waxing treated areas. Store at 20-25°C, allowing 15-30°C excursions, away from heat.
Use the Arazlo-specific precautions
Arazlo is tazarotene 0.045% lotion for acne from age nine, applied thinly once daily. Separate it from benzoyl peroxide by using different times of day. Pregnancy is contraindicated: obtain a negative test within two weeks before starting, begin during a menstrual period, and use effective contraception. Stop if pregnancy occurs. Store at 20-25°C, allowing 15-30°C excursions; protect from freezing.
Separate breastfeeding from pregnancy
Breastfeeding requires a product-specific benefit-risk discussion. Aklief and Arazlo lack human milk and infant-effect data; their labels advise the shortest feasible use and no application to the nipple or areola. Aklief also specifies the smallest treated area. These precautions do not establish absence of risk, but neither label treats breastfeeding as the pregnancy contraindication.
Protect the reproductive plan
Topical retinoids are avoided during pregnancy. Ask about pregnancy status and goals before recommending a prescription or OTC retinoid and reconcile cosmetic products that may contain retinoid ingredients.
Quick check
Checking for saved practice…
Lesson
Build Complementary Topical Therapy
Benzoyl peroxide, topical antibiotics, azelaic acid, and salicylic acid have different roles. Combination therapy should increase mechanism coverage without creating avoidable resistance or dermatitis.
- Benzoyl peroxide
- Clindamycin
- Azelaic acid
- Salicylic acid
- Barrier support
Reduce bacterial burden and support stewardship
Never leave antibiotic therapy unprotected and open ended
Address acne and postinflammatory pigment with tolerability
Avoid stacked irritants and product duplication
Use benzoyl peroxide deliberately
Benzoyl peroxide provides oxidizing antibacterial activity and helps protect antibiotic stewardship. Lower strengths can be effective with less irritation. Counsel that it can bleach fabric and hair and that wash-off and leave-on vehicles have different contact patterns.
Never leave a topical antibiotic alone
Use topical clindamycin or another antibiotic with benzoyl peroxide and for a defined duration. Maintain control afterward with nonantibiotic therapy rather than continuing antibiotic monotherapy indefinitely.
Use nonantibiotic alternatives purposefully
Azelaic acid can address acne and postinflammatory pigment change, while salicylic acid can help comedonal disease. Concentration, vehicle, frequency, sensitive skin, and pregnancy context matter.
Distinguish azelaic-acid products
Azelex is azelaic acid 20% cream, labeled for mild-to-moderate inflammatory acne. After washing and drying, apply a thin film twice daily and wash the hands. Use below age twelve is unestablished. Avoid occlusion and mucosal contact; stop for severe irritation or sensitivity and report abnormal lightening of skin. Store on its side at 15-30°C and protect from freezing.
Separate the Finacea indication
Finacea gel contains azelaic acid 15% and is labeled for inflammatory papules and pustules of mild-to-moderate rosacea. Acne use is outside that labeled indication. Apply a thin layer twice daily for its prescribed purpose; persistent severe irritation, hypersensitivity, pigment loss or worsening asthma warrants review. Brand, concentration, vehicle and indication must be checked together.
Use topical dapsone with its own safety review
Dapsone 7.5% gel is labeled from age nine: apply a thin layer once daily, using about a pea-sized amount for the face, and reassess absent improvement at twelve weeks. G6PD deficiency increases hematologic risk but is not a listed contraindication. Obtain an individualized prescribing assessment; the label advises avoiding congenital or idiopathic methemoglobinemia, concurrent oral dapsone and antimalarials. TMP-SMX can increase exposure and hemolysis risk.
Distinguish discoloration from a blood emergency
Stop dapsone and seek immediate care for blue-gray lips, mouth or nail beds. Stop and obtain assessment for suspected hemolytic anemia. Benzoyl peroxide applied with topical dapsone can cause temporary local yellow-orange discoloration; this differs from cyanosis. Review timing and distribution rather than dismissing every color change as harmless.
Check the exact adapalene combination
Epiduo gel contains adapalene 0.1% with benzoyl peroxide 2.5% and is labeled from age nine. After gentle washing and drying, apply a thin film once daily; use a pea-sized amount for each facial region, such as the forehead, chin or each cheek. Keep it away from eyes, lips and mucosa. Avoid damaged or eczematous skin and waxing treated skin. Irritation may require moisturizer, reduced frequency or stopping. Protect from light and heat; store at 25°C with permitted excursions of 15-30°C.
Do not substitute a psoriasis combination
Duobrii combines halobetasol propionate 0.01% with tazarotene 0.045%. Its labeled use is adult plaque psoriasis, not acne, and its directions exclude the face, groin and axillae. The presence of a retinoid does not make this corticosteroid combination interchangeable with an acne retinoid. It is contraindicated in pregnancy. Clarify an acne-directed prescription before use.
Prepare Benzamycin by its own directions
The labeled Benzamycin kit supplies erythromycin 3% with benzoyl peroxide 5% after preparation. For the 46.6 g kit, dissolve the powder with 6 mL of 70% ethyl alcohol, then incorporate the solution into the gel until uniform. Before mixing, store at 15-30°C; afterward, refrigerate at 2-8°C without freezing and label for disposal three months after mixing. It is applied twice daily to cleansed, dry affected skin. Verify the dispensed product rather than borrowing another combination gel’s instructions.
Distinguish the BenzaClin kit
BenzaClin provides clindamycin 1% with benzoyl peroxide 5%. Its kit uses purified water: 5, 7 or 10 mL for the labeled 25, 35 or 50 g presentation, respectively. Dissolve the powder and stir the solution into the gel until uniform. After mixing, keep tightly closed at room temperature up to 25°C, do not freeze, and label a three-month discard date. Apply twice daily after gentle washing and drying. These directions do not automatically apply to other clindamycin combinations.
Screen topical antibiotic safety
For BenzaClin, a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis is a contraindication, as is hypersensitivity to its components or lincomycin. Stop for significant diarrhea and obtain clinical assessment, especially with blood or severe cramps. Avoid combining clindamycin with erythromycin products. Topical administration does not eliminate systemic adverse effects.
Keep dapsone formulations distinct
Dapsone 5% gel is applied twice daily after gentle cleansing and drying; rub a thin, approximately pea-sized amount into affected areas and wash the hands. Reassess if there is no improvement after twelve weeks. Its labeling does not recommend use below age twelve. Do not transfer the 7.5% gel’s once-daily schedule or age-nine indication to the 5% formulation.
Apply topical minocycline correctly
Amzeeq 4% foam treats inflammatory lesions of non-nodular moderate-to-severe acne from age nine. Shake, dispense a small amount onto fingertips and rub into affected skin once daily, at least an hour before bed. Avoid bathing, swimming or showering for one hour afterward. It is not an infection treatment.
Handle the foam safely
Keep Amzeeq refrigerated at 2-8°C before dispensing. At home, store below 25°C for 90 days, without refrigeration. Let the can reach room temperature before first use. Avoid flames and smoking during and immediately after application; never puncture or burn the can.
Retain tetracycline precautions
Amzeeq is contraindicated with tetracycline or ingredient allergy. Avoid isotretinoin coadministration. Stop and seek assessment for unusual headache or visual symptoms, suspected liver injury, severe diarrhea or autoimmune symptoms; serious allergy needs emergency care. Many label warnings derive from oral minocycline experience, not established equal risk with foam. Breastfeeding is not recommended during treatment; pregnancy requires clinician review.
Resolve dapsone use during breastfeeding
Low systemic absorption does not establish infant safety. The dapsone 5% professional label reports no topical milk or infant-effect data; oral exposure can cause infant hemolysis and hyperbilirubinemia, particularly with G6PD deficiency. Its patient leaflet advises choosing treatment or breastfeeding, not both. Discuss an alternative acne regimen with the prescriber rather than reassuring that topical use is automatically safe.
Prevent ingredient pileup
A retinoid, benzoyl peroxide, acids, astringents, scrubs, and fragranced products can collectively injure the barrier. Build a morning and evening schedule, introduce changes deliberately, and reduce the least essential irritant first.
Quick check
Checking for saved practice…
Lesson
Use a Local Androgen Receptor Strategy
Clascoterone is a topical androgen receptor inhibitor labeled for acne vulgaris in patients 12 years and older. Local use still requires product-specific exposure and safety reasoning.
- Androgen receptor
- Age 12 and older
- Twice-daily use
- Local irritation
- HPA axis signal
Target a local signaling pathway
Respect indication, amount, frequency, and site
Reduce or stop when the barrier is injured
Exposure area, age, skin integrity, and symptoms matter
Keep the mechanism precise
Clascoterone inhibits the androgen receptor, but its exact mechanism of clinical acne improvement is not fully established. Do not describe it as simply topical spironolactone or assume identical systemic effects.
Follow current labeling
Current labeling indicates clascoterone cream 1 percent for patients age 12 and older. Apply a thin uniform layer to the affected area twice daily and avoid eyes, mouth, mucous membranes, and noncutaneous routes.
Distinguish pharmacy and home storage
Before dispensing, refrigerate Winlevi at 2-8 degrees C. During patient use, keep it at 20-25 degrees C. Do not freeze. Record both dispensing and opening dates; discard at the earlier of 180 days after dispensing or one month after opening.
Respond to local injury
Pruritus, burning, redness, peeling, dryness, edema, and stinging can occur. Reduce frequency or stop according to clinician and label guidance when meaningful irritation develops. Do not apply to eczema, cuts, abrasions or sunburned skin.
Respect systemic signals
HPA axis suppression occurred in adults and adolescents in a small pharmacokinetic study. Large treated areas, prolonged use and occlusion increase absorption; children may be more susceptible. If suppression develops, the clinician should attempt withdrawal. Potassium elevations occurred in both active-treatment and vehicle groups; this observation does not establish a universal testing schedule.
Quick check
Checking for saved practice…
Lesson
Use Oral Antibiotics as a Bridge
Oral tetracycline-class antibiotics can control moderate to severe inflammatory acne, but stewardship requires benzoyl peroxide, a topical foundation, product-specific administration, reassessment, and an exit.
- Doxycycline
- Minocycline
- Sarecycline
- Cation chelation
- Antibiotic duration
Use systemic therapy for meaningful inflammatory disease
Pair with topical nonantibiotic mechanisms
Manage cations, posture, food, light, and swallowing
Stop, change mechanism, or escalate rather than drift
Start with indication and companion therapy
Oral doxycycline has strong guideline support, while minocycline and sarecycline are additional options. Combine systemic antibiotics with benzoyl peroxide and other topical therapy rather than using systemic antibiotic monotherapy.
Reserve alternative antibiotics for a specific reason
Do not treat every oral antibiotic as an interchangeable acne option. The 2024 AAD guideline finds insufficient evidence to recommend oral azithromycin or TMP-SMX for acne. It describes earlier guidance restricting TMP-SMX to patients unable to tolerate tetracyclines and limited macrolide use in pregnancy. Broad use risks resistance in drugs needed for other infections. TMP-SMX also carries potentially severe skin and respiratory toxicity. Pregnancy or tetracycline intolerance requires an individualized clinician-led regimen, not automatic substitution with erythromycin or TMP-SMX.
Limit duration
Use the shortest effective course, typically no more than 3-4 months, with planned reassessment. Longer treatment requires a documented reason and repeated review rather than automatic refills. Transition to a nonantibiotic maintenance regimen after control. Persistent nodules, scars, or adequate-course failure should trigger a mechanism change or isotretinoin and dermatology discussion.
Teach product-specific administration
Tetracyclines can interact with iron, calcium, magnesium, aluminum, bismuth, and other polyvalent cations. Food instructions differ by product. Adequate water and upright posture can reduce esophageal injury for relevant formulations.
Choose a defined doxycycline acne regimen
NICE provides doxycycline 100 mg orally once daily as an acne regimen with a topical partner, reviewed after 12 weeks. This is a guideline-supported example, not a universal dose for every formulation or patient. The AAD also describes evidence for lower-dose regimens but finds insufficient direct comparisons to select one optimal dose. Confirm the prescription, formulation and patient factors; do not borrow a loading-dose schedule from an unrelated infection indication.
Make doxycycline administration workable
Take doxycycline with adequate water while upright and avoid taking it immediately before bed. The reviewed immediate-release hyclate tablet permits food or milk for gastric irritation; antacids, iron and bismuth still interfere with absorption. Check the actual formulation before imposing food restrictions or permitting tablet splitting. Carbamazepine, phenytoin and barbiturates can shorten doxycycline exposure; review the full medicine list.
Keep doxycycline safety tied to the indication
Acne treatment does not justify the exceptional doxycycline use in young children with life-threatening infections. Review pregnancy and feeding plans. The reviewed hyclate label advises against breastfeeding during treatment and for five days afterward. Counsel about sun sensitivity, esophageal injury, severe skin reactions and persistent or bloody diarrhea. Avoid isotretinoin coadministration; headache with visual symptoms warrants prompt assessment. Prolonged therapy requires periodic blood-count, renal and hepatic evaluation.
Reconcile antibiotic and contraceptive advice
Some doxycycline labels warn that oral contraception may become less effective. The 2024 U.S. MEC classifies broad-spectrum antibiotics as category 1 for combined hormonal contraception: most do not reduce effectiveness. Doxycycline alone therefore does not create a routine requirement for backup contraception. Rifampin and rifabutin are different; their enzyme induction can reduce effectiveness. Assess the actual interacting drug and contraceptive method rather than applying one rule to every antibiotic.
Dose sarecycline by its labeled weight band
Seysara treats inflammatory lesions of non-nodular moderate to severe acne from age 9. Once-daily doses are 60 mg at 33-54 kg, 100 mg at 55-84 kg and 150 mg at 85-136 kg. Do not extrapolate outside the labeled bands. Take with or without food and enough fluid. Reassess absent improvement at 12 weeks; efficacy beyond 12 weeks is unestablished.
Check sarecycline reproductive and interaction risks
Avoid Seysara in men attempting conception because of animal fertility findings. Stop if pregnancy occurs; breastfeeding is not recommended. Separate antacids, iron and bismuth; avoid oral retinoids and penicillin coadministration. Review anticoagulants and monitor susceptible P-glycoprotein substrates such as digoxin for toxicity. Tetracycline allergy precludes use.
Give sarecycline a symptom action plan
Stop and obtain prompt assessment for headache or visual change suggesting intracranial hypertension, or significant watery or bloody diarrhea. Use sun protection and stop for sunburn; dizziness can impair driving. Store at 20-25 degrees C, allowing 15-30-degree excursions, protected from moisture and excessive heat.
Keep extended-release minocycline product specific
Solodyn is labeled from age 12 for inflammatory, non-nodular moderate to severe acne. Use its weight table, approximately 1 mg/kg once daily for 12 weeks; higher doses add vestibular risk without demonstrated extra benefit. Swallow whole, with or without food; do not split, crush or chew. Renal impairment requires dose reduction or longer intervals. Verify available strengths and the exact extended-release product rather than substituting an immediate-release schedule.
Monitor minocycline beyond routine irritation
Solodyn labeling calls for periodic blood-count, kidney and liver assessments. The Solodyn counseling instructions advise stopping and contacting the clinician immediately for new skin redness; do not wait for a severe rash. Fever with systemic illness, suspected liver injury, or headache with visual changes requires urgent evaluation. Anaphylaxis requires emergency care. Autoimmune syndromes and tissue pigmentation are additional concerns. Avoid isotretinoin coadministration. Stop if pregnancy occurs; breastfeeding is not recommended during Solodyn therapy or for four days after its final dose.
Screen predictable harm
Review pregnancy, age, photosensitivity, swallowing and reflux, vestibular symptoms, pigmentation or autoimmune concerns with selected agents, liver and kidney context, allergy, intracranial hypertension risk, and isotretinoin coadministration.
Quick check
Checking for saved practice…
Lesson
Select Hormonal Therapy Through the Whole Patient
Combined oral contraceptives and spironolactone can improve selected persistent acne, but the acne phenotype never replaces contraceptive, cardiovascular, renal, interaction, and reproductive assessment.
- Combined oral contraceptives
- Spironolactone
- Androgen pattern
- VTE risk
- Potassium risk
Use phenotype as one clue, not the only criterion
Apply full eligibility and thrombosis reasoning
Individualize kidney, potassium, pressure, and interaction review
Acne benefit must fit pregnancy plans and preferences
Use combined contraception only when eligible
Selected combined oral contraceptives can improve acne. Screen pregnancy goals, migraine with aura, blood pressure, smoking, VTE history, postpartum status, age, interacting medicines, and adherence using current contraceptive guidance.
Apply contraceptive eligibility categories
Under the 2024 U.S. MEC, combined hormonal contraception is category 4, an unacceptable risk, with migraine with aura or blood pressure at least 160 mmHg systolic or 100 mmHg diastolic. Controlled hypertension or systolic pressure of 140-159 mmHg or diastolic pressure of 90-99 mmHg are category 3, meaning risks usually outweigh benefits. Confirm blood pressure appropriately; one reading alone does not establish hypertension. Acne benefit does not override these restrictions.
Assess smoking alongside age
For combined hormonal contraception, smoking at age 35 or older is category 3 below fifteen cigarettes daily and category 4 at fifteen or more. Smoking below age 35 is category 2, but other cardiovascular risks still matter. Review the full eligibility guidance when several risks coexist.
Use spironolactone as a systemic antiandrogen
Spironolactone is used off-label for acne and can help selected patients with persistent disease; an abnormal androgen test is not required to consider it. Counsel about menstrual change, breast tenderness, diuresis, dizziness, and the need to avoid pregnancy during therapy. Take Aldactone consistently with respect to meals because food changes its absorption.
Individualize potassium monitoring
The AAD acne guideline does not require routine potassium monitoring in healthy patients without risk factors. Older age, kidney disease, comorbidities or potassium-raising medicines change that assessment. The Aldactone label advises potassium testing within one week of starting or increasing a dose and regularly afterward, with closer testing for renal impairment or interacting drugs. Document why the selected monitoring plan fits this patient.
Check spironolactone contraindications
Do not use spironolactone with hyperkalemia, Addison disease or eplerenone. Reconcile potassium supplements and salt substitutes, ACE inhibitors, ARBs, trimethoprim and NSAIDs before prescribing. Spironolactone can also increase lithium exposure: concurrent therapy requires a prescriber-led plan for lithium levels and toxicity monitoring. Assess renal function and volume status when clinically indicated; hypotension, dehydration or declining renal function requires reassessment rather than automatic dose escalation.
Set realistic expectations
Combined oral contraceptives often show acne improvement over 3-6 months. They are not restricted to jawline acne or premenstrual flares. Measure inflammatory lesions, cyclical flares, adverse effects, blood pressure when relevant, adherence, and patient goals before escalating or abandoning therapy.
Quick check
Checking for saved practice…
Lesson
Control Isotretinoin Risk Without Delaying Needed Care
Isotretinoin can transform severe, scarring, refractory, or deeply burdensome acne. Its benefit depends on rigorous embryo-fetal protection, interaction review, targeted monitoring, and symptom counseling.
- Candidacy
- iPLEDGE REMS
- Pregnancy prevention
- Laboratory monitoring
- Serious symptoms
Include scarring and psychosocial harm
Use the current iPLEDGE REMS workflow exactly
Follow pregnancy, liver, lipid, symptom, and interaction risk
Separate dryness from serious headache, vision, mood, or abdominal signals
Recognize candidacy
Severe nodular disease is a classic indication. Current acne guidance also supports isotretinoin for severe acne or failure of standard oral or topical therapy, with scarring and psychosocial burden informing the decision.
Use current iPLEDGE rules
Isotretinoin causes severe embryo-fetal harm. Follow the current patient category, pretreatment and follow-up testing, counseling, authorization, contraception or abstinence requirements, prescription window, and dispensing workflow exactly. As checked September 26, 2026, FDA delayed implementation of the February 2026 modifications from August 8 to November 15, 2026. Do not treat the approval date as the effective date. FDA continues pregnancy-testing enforcement discretion during the transition: pretreatment tests remain in a medical setting; prescribers may permit home testing during and after therapy with safeguards against misinterpretation or falsification. Verify the live program before each dispensing decision.
Make pregnancy prevention explicit
Patients who can become pregnant must use two program-accepted contraceptive methods together or commit to avoiding sexual contact that could result in pregnancy, beginning one month before treatment and continuing through one month afterward. A missed period, suspected pregnancy or intercourse outside the prevention plan requires stopping treatment and contacting the prescriber immediately. Follow the current REMS testing and response requirements.
Check the actual contraceptive methods
When contraception is chosen, at least one method must be a program-accepted primary method. Examples include an IUD, implant or combined hormonal contraceptive, paired with an accepted secondary method such as a male latex condom. The Absorica label identifies estrogen-free minipills as inadequate for this purpose; do not confuse them with progestin implants or IUDs, which are listed primary options. Confirm the current program list and individual eligibility rather than assuming that any two methods qualify. Reconcile herbal supplements, including St. John's wort, with the prescriber before use.
Complete each dispensing authorization
The pharmacy must verify enrollment and obtain and document the required iPLEDGE authorization for each prescription. Dispense no more than a 30-day supply and observe the current do-not-dispense-after date. Supply the Medication Guide and review it with the patient. Automatic refills are prohibited. For patients who can become pregnant, the specimen-collection date is day one of the seven-day window; use the system-generated deadline. If a prescription is not collected within its authorized window, reverse the RMA and return the medicine to inventory. Future program changes do not authorize dispensing outside the currently implemented workflow.
Keep isotretinoin formulations distinct
Absorica and Absorica LD have different bioavailability and are not substitutable. Their labeled daily ranges are respectively 0.5-1 mg/kg and 0.4-0.8 mg/kg, divided into two doses for 15-20 weeks, with or without meals. Confirm the exact product instead of applying a class-wide food or dose rule. A missed dose is skipped; do not double.
Check food requirements on the dispensed capsule
The reviewed Aurobindo isotretinoin capsule label specifies 0.5-1 mg/kg/day in two divided doses with food for 15-20 weeks. This differs from the meal-independent Absorica instructions. A generic drug name alone does not identify the formulation: confirm the actual label before counseling or changing products. The capsule must remain whole; a calculated dose that does not match available strengths needs a prescriber-approved regimen, not capsule splitting.
Calculate the daily dose before dividing it
For an 80 kg patient, 0.5 mg/kg/day gives 40 mg per day, or 20 mg twice daily. For Absorica LD at 0.4 mg/kg/day, the same weight gives 32 mg per day, or 16 mg twice daily. These are calculations at the respective labeled lower dose limits, not interchangeable prescriptions. The prescriber adjusts treatment to response, tolerability and the exact product.
Preserve capsule integrity
Swallow Absorica or Absorica LD whole with a full glass of liquid. Do not puncture, split, crush, chew or suck the capsule. If swallowing is difficult, obtain a pharmacist and prescriber plan rather than opening it into food.
Counsel beyond the prescription
Do not share isotretinoin or donate blood during treatment and for one month afterward. Protect the capsules from light and store at 20-25 degrees C, with permitted excursions of 15-30 degrees C. For Absorica and Absorica LD, breastfeeding is not recommended during treatment or for at least eight days after the last dose; confirm the exact product and the infant-feeding plan with the treating team. This interval does not shorten the separate one-month pregnancy-prevention requirement.
Monitor targeted risks
Review pregnancy prevention when applicable, lipids, liver context, mucocutaneous toxicity, headache and vision, mood, musculoskeletal symptoms, alcohol, vitamin A, tetracyclines, and other medicines. Avoid concurrent tetracyclines because of intracranial hypertension risk.
Establish the monitoring baseline
Before Absorica or Absorica LD, obtain fasting lipids including triglycerides and liver tests, plus required pregnancy assessment. Repeat fasting lipids and liver tests periodically until the response is established; the lipid response is usually known within four weeks. Higher-risk patients need closer checks. Follow the label instruction to wait at least 36 hours after alcohol consumption before lipid testing. Suspected hepatitis or liver enzyme elevations that do not readily normalize require discontinuation. Uncontrolled hypertriglyceridemia requires discontinuation. A normal triglyceride result does not exclude pancreatitis.
Act on stop-treatment warnings
Stop isotretinoin and seek prompt assessment for new depression, major mood disturbance, psychosis or aggression; stopping alone may not resolve the problem. Suspected pregnancy requires immediate discontinuation and specialist counseling. Stop and obtain urgent evaluation for suspected pancreatitis or a severe skin reaction. New tinnitus or hearing impairment requires discontinuation and specialist assessment. Suicidal intent or another immediate danger requires emergency help.
Separate expected from urgent
Dry lips and skin are common and deserve proactive barrier care. Stop treatment and obtain urgent assessment for severe headache with visual symptoms, abdominal pain, rectal bleeding or severe diarrhea. New visual difficulty requires discontinuation and an eye examination; impaired night vision can begin suddenly and persist, so avoid unsafe night driving. These warning actions do not establish that isotretinoin caused a particular condition.
Review musculoskeletal and ingredient risks
The Medication Guide directs patients with muscle or joint pain or weakness to stop treatment and contact the prescriber promptly. Weakness can signal serious muscle injury. Review strenuous exercise and bone-health risks; report bone or back pain and fractures. Check inactive ingredients: the Absorica 25 mg capsule contains tartrazine, which can cause allergic reactions in susceptible patients; the other Absorica strengths and Absorica LD do not contain that dye.
Quick check
Checking for saved practice…
Lesson
Make Acne Care Sustainable and Stage Appropriate
A high-quality acne plan is simple enough to use, long enough to judge, safe for the patient's life stage, and explicit about reassessment, maintenance, and escalation.
- Gentle skin care
- Adherence
- Pregnancy
- Pediatrics
- Maintenance
Assign one purpose to every product
Use gentle care, moisturizer, and sunscreen
Reconcile every active and exact label
Track lesions, scars, pigment, distress, adherence, and duration
Design the daily system
Use gentle cleansing, noncomedogenic moisturizer, sunscreen, and a clear sequence. Ask about cosmetics, hair products, masks, helmets, occupational occlusion, picking, and cost. Simplify before declaring treatment failure.
Judge response fairly
Retinoids and other therapies require weeks to show prevention. Document baseline morphology and reassess on a planned timeline, while escalating earlier for nodules, scars, severe distress, pregnancy concern, or significant adverse effects.
Reconcile pregnancy and age
Avoid retinoids during pregnancy and review tetracyclines, hormonal agents, isotretinoin, and every OTC or cosmetic active. Unusually early acne, virilization, rapid onset, or endocrine symptoms requires a broader assessment.
Discuss diet and supplements honestly
The 2024 AAD review found insufficient evidence to recommend specific dietary restrictions or botanical and vitamin products as acne treatments. Ask about supplements and perceived triggers without presenting a restrictive diet or tea tree oil as a substitute for effective care. Insufficient evidence does not establish either benefit or lack of benefit.
Refer procedural decisions
A clinician may use an intralesional corticosteroid for selected large, painful acne lesions; local atrophy is a risk. Before any peel, laser, waxing or resurfacing procedure, disclose isotretinoin use. Product labeling and procedure-specific specialist guidance differ, so obtain an individualized plan.
Maintain without antibiotics
After control, continue the least burdensome effective nonantibiotic regimen. Track new lesions, pigment, scars, irritation, quality of life, and adherence so recurrence is addressed before permanent harm returns.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 119 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- iPLEDGE. Pharmacist Guide, March 2023; read with current program updates
- DailyMed. Aurobindo isotretinoin capsules, August 2026
- NICE NG198. Acne vulgaris: management
- DailyMed. Absorica/Absorica LD Medication Guide, June 2026
- DailyMed. Lupin doxycycline hyclate tablets, September 2025
- FDA. Solodyn prescribing information, April 2025
- DailyMed. Seysara prescribing information, March 2023
- CDC. 2024 U.S. MEC: combined hormonal contraceptives
- Pfizer. Aldactone prescribing information, November 2025
- DailyMed. Amzeeq 4% foam prescribing information
- DailyMed. Dapsone 5% gel prescribing information, July 2026
- DailyMed. Aklief prescribing information
- DailyMed. Arazlo prescribing information
- DailyMed. BenzaClin kit prescribing information
- DailyMed. Benzamycin kit prescribing information
- DailyMed. Epiduo 0.1%/2.5% prescribing information, June 2026
- Duobrii prescribing information
- FDA. Absorica and Absorica LD prescribing information, August 2026
- DailyMed. Dapsone 7.5% gel, revised June 2025
- DailyMed. Azelex 20% cream, Almirall 2024
- DailyMed. Finacea 15% gel prescribing information
- American Academy of Dermatology Acne Clinical Guideline
- FDA iPLEDGE REMS
- FDA Questions and Answers on iPLEDGE
- DailyMed Clascoterone Label